Protein kinase D inhibitors
View Patent ↗Compounds according to Formula (I), are potent inhibitors of protein kinase D (pan-PKD) activity. PKD controls key signaling cascades in cells, affecting cell proliferation, gene transcription, and protein trafficking. Accordingly, pharmaceutically acceptable compositions of the inventive compounds are candidate therapeutics for pathological conditions conditioned by changes in PKD activity.
1. A compound according to Formula I,
wherein
R 1 , R 2 , R 3 , and R 4 are each independently selected from the group consisting of hydrogen, straight or branched chain (C 1 -C 6 )alkyl, (C 2 -C 6 )alkene, halogen, —OH, —OR′, —OC(O)CH 3 , (C 1 -C 6 )alkoxy, —N 3 , —NR′R″, isocyanate, isothiocyanate, straight or branched (C 1 -C 6 )haloalkyl and straight or branched (C 1 -C 6 )haloalkoxy;
R 5 is selected from the group consisting of hydrogen, a straight or branched chain (C 1 -C 6 )alkyl, (C 1 -C 6 )alkylene-NH 2 , (C 1 -C 6 )alkoxy, and —C(O)—(C 1 -C 6 )alkyl;
each of X and X′ is a —C— or —N—;
Y is —S—;
Z is —S—; and
n is 1;
wherein R′, R″, R a , R b and R d are each independently selected from the group consisting of H, straight or branched (C 1 -C 6 )alkyl, (C 2 -C 6 )alkene, (C 2 -C 6 )alkenyloxy, halogen, —OH, —OC(O)CH 3 , —C(O)CH 3 , —C(O)CH 2 -halide, straight or branched (C 1 -C 6 )haloalkyl, and benzyl,
wherein R 1 is only present when X is C, and R 3 is only present when X′ is C,
or a pharmaceutically acceptable salt, stereoisomer, tautomer, or prodrug thereof.
2. The compound according to claim 1 , wherein R 2 is —OH.
3. The compound according to claim 1 , wherein R 2 is (C 1 -C 6 )alkoxy.
4. The compound according to claim 3 , wherein R 2 is methoxy.
5. The compound according to claim 1 , wherein R 2 is an azide.
6. The compound according to claim 1 , wherein each of X and X′ is —N—.
7. The compound according to claim 1 , wherein each of X and X′ is —CH—.
8. The compound according to claim 1 , wherein R 2 is H.
9. The compound according to claim 1 that is selected from the following table:
10. A pharmaceutical composition comprising a therapeutically effective amount of at least one compound according to claim 1 , or a pharmaceutically acceptable salt, tautomer, or prodrug thereof; and a pharmaceutically acceptable carrier.
11. A method for inhibiting PKD1 in a cell, comprising contacting the cell with at least one compound according to claim 1 .